Jacobson Pharma to Acquire Saplingtan, Shiling Oil & Col-gan Tablet

Well-positioned to penetrate further into the OTC drug markets in Hong Kong, China and Asia Pacific

HONG KONG —┬áJacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Group”; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its acquisition of a family of popular household brands, namely, Saplingtan, Shiling Oil and Col-gan Tablet.

Saplingtan and Shiling Oil are both popular household brands with close to a century of heritage enjoying a high brand awareness amongst the Chinese consumers in Hong Kong, China and various other overseas markets. Added under the umbrella is Col-gan Tablet which has all along been prevailing as a popular and well-recognized brand in the cold and flu market segment.

These newly acquired brands are highly complementary to Jacobson’s current proprietary medicine portfolio and it opens a new set of opportunities for the Group to strengthen its market presence in the OTC channels. This acquisition represents yet another important strategic move for the Group to realize its strategy of building a family of well-known and trusted household proprietary brands with a wide geographical presence in Asia spanning from Hong Kong, China to Malaysia and Indonesia, etc.

With the successful completion of the acquisition of Ho Chai Kung on 16 January 2017, Jacobson Pharma’s proprietary medicine portfolio now carries brands like Po Chai Pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok Oil, Contractubex Scar Gel, Doan’s Ointment and Flying Eagle Wood Lok Medicated Oil. All these household brands carry a high recognition amongst the consumers and enjoy a strong market position thus creating sustainable synergies for marketing and distribution resources.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma said, “The acquisition is an important step forward in reinforcing Jacobson Pharma’s strategy to acquire brands that bring about a sound strategic fit to our long term business development. This strategic acquisition accelerates the growth momentum of our proprietary medicine business and facilitates our penetration into China and other Asian Pacific markets. It also helps create a high level of synergies through leveraging of marketing and distribution resources.”

Mr Sum further added, “The adding of an array of popular household brands like Saplingtan, Shiling Oil and Col-gan Tablet to our current portfolio will help create an expandable Proprietary Medicine platform rendering us well-positioned to enhance our geographical reach amongst the key strategic markets in Asia Pacific.”